Allyson Thatcher, MD
Interventional Pain Medicine · North Charleston, SCNPI 1922047380
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,530 of the $4,350 with a category attached, or 81.1%. 29 manufacturers reported payments, led by Medtronic at 43.3% of the total. Reporting peaked in 2022 at $2,042 and has fallen 79.3% since, to $423 in 2025.
Across 157 payments — averaging $27.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Tersera Therapeutics LLC$469
- Collegium Pharmaceutical, Inc.$451
- Averitas Pharma Inc.$235
- GRT US Holding, Inc.$159
- Vertos Medical, Inc.$133
- plus $1K from 23 others
What the payments were for
- Travel & lodging$82019%
- Food & beverage$3,53081%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 21 | $1,886 |
| Tersera Therapeutics LLC | 24 | $469 |
| Collegium Pharmaceutical, Inc. | 32 | $451 |
| Averitas Pharma Inc. | 8 | $235 |
| GRT US Holding, Inc. | 9 | $159 |
| Vertos Medical, Inc. | 3 | $133 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $111 |
| AbbVie | 5 | $105 |
| Scilex Pharmaceuticals Inc. | 6 | $104 |
| IBSA Pharma Inc. | 6 | $93 |
| Redhill Biopharma Inc. | 5 | $79 |
| Biodelivery Sciences International, Inc. | 5 | $73 |
| Pfizer | 4 | $62 |
| Protega Pharmaceutials Inc | 3 | $47 |
| Amgen | 2 | $42 |
| Virtus Pharmaceuticals LLC | 2 | $40 |
| Arbor Pharmaceuticals, Inc. | 3 | $39 |
| AstraZeneca | 2 | $29 |
| Saluda Medical Americas, Inc. | 1 | $28 |
| Boston Scientific | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Vertex | 1 | $20 |
| Forte Bio-pharma LLC | 1 | $18 |
| Abbott | 1 | $13 |
| Kaleo, Inc. | 1 | $13 |
| Bioventus LLC | 1 | $12 |
| Almatica Pharma LLC | 1 | $12 |
| Nevro Corp. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMEDII$1,223
How this compares
$4,350 in reported general payments places this provider in the 60th percentile of 38 interventional pain medicine providers in South Carolina.
See all interventional pain medicine providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 124 | $90,343 |
| BelbucaBuprenorphine Hcl | 97 | $78,913 |
| Buprenorphine | 152 | $31,448 |
| OxycontinOxycodone Hcl | 30 | $31,417 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 594 | $15,906 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 480 | $14,146 |
| LinzessLinaclotide | 22 | $11,956 |
| Fentanyl | 106 | $9,654 |
| Naloxone Hcl | 150 | $9,209 |
| Morphine Sulfate ErMorphine Sulfate | 209 | $7,436 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 29 | $6,104 |
| Tramadol Hcl ErTramadol Hcl | 65 | $4,586 |
| Oxycodone Hcl | 290 | $4,241 |
| Pregabalin | 164 | $3,209 |
| Gabapentin | 216 | $3,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $451 | $169,256221 claims |
| AbbVieLinzess | $105 | $11,95622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 38 interventional pain medicine providers in South Carolina.
Other interventional pain medicine in North Charleston
- Mark NethertonMt Pleasant$102K
- Marion McMillanSeneca$89K
- Jason RosenbergMurrells Inlet$82K
- Ryan NoblesMt Pleasant$43K
- Justin HutchesonGreenville$23K
- Joshua BighamSpartanburg$14K
- David RoweBluffton$9K
- William DurrettAiken$8K
- Kenneth GrosslightWest Columbia$7K
- Phillip SuwanAiken$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.